ByTrending Posts
Did 2025 Expose the Breaking Point of America’s…
New reflections from healthcare leaders highlight how events in 2025 revealed deep structural weaknesses in the U.S. health…
How Is Senhwa Biosciences Using AI and Strategic…
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
Will the European Commission’s New Health Policy Package…
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis…
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in…
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
Has the FDA Approval of Breyanzi Expanded CAR…
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Does a New Kidney Cancer Trial Expand Long-Term…
December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of…
Is Gilead’s Experimental HIV Treatment Matching the Efficacy…
Foster City, California — Gilead Sciences has reported that its experimental HIV treatment has met the primary goal…
Is the White House (Trump) Expanding Its Drug…
Washington, D.C. — The U.S. administration has announced a new set of agreements with nine pharmaceutical companies to…
Trending Posts
Latest Stories
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S.…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally…
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed,…
Gallery
